within Pharmacolibrary.Drugs.ATC.C;

model C09BB13
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 1.9999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013833333333333334,
    Tlag           = 600,            
    Vdp             = 0.06,
    k12             = 20,
    k21             = 20
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09BB13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Benazepril is an angiotensin-converting enzyme (ACE) inhibitor used primarily for the treatment of hypertension and heart failure; amlodipine is a dihydropyridine calcium channel blocker used to treat hypertension and angina. The fixed combination is used in adults to lower blood pressure and reduce cardiovascular risk, and is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated based on published data for individual components (benazepril and amlodipine) in healthy adults; no direct published compartmental PK parameters found for the fixed combination.</p><h4>References</h4><ol><li><p>Song, H, et al., &amp; Bai, W (2025). Bioequivalence Study of Single-Pill Capsule Formulation of Amlodipine Plus Benazepril in Healthy Chinese Subjects Under Fasting and Fed Conditions. <i>Drug design, development and therapy</i> 19 1853–1868. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S498337&quot;>10.2147/DDDT.S498337</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40098905/&quot;>https://pubmed.ncbi.nlm.nih.gov/40098905</a></p></li><li><p>Pan, HL, et al., &amp; Zhong, DF (2014). [Simultaneous determination of amlodipine, benazepril and benazeprilat in human plasma by LC-HESI/MS/MS method]. <i>Yao xue xue bao = Acta pharmaceutica Sinica</i> 49(1) 95–100. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24783513/&quot;>https://pubmed.ncbi.nlm.nih.gov/24783513</a></p></li><li><p>Scott, LJ, &amp; McCormack, PL (2008). Olmesartan medoxomil: a review of its use in the management of hypertension. <i>Drugs</i> 68(9) 1239–1272. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200868090-00005&quot;>10.2165/00003495-200868090-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18547134/&quot;>https://pubmed.ncbi.nlm.nih.gov/18547134</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09BB13;
